Finerenone Therapy for Pediatric HSPN With Mild Proteinuria

Condition(s) studied

Investigational drug(s) / intervention(s)

ACEI / ARB+finerenone: In the finerenone group, finerenone was administered orally on the basis of combined oral ACEI/ARB, with the dose calculated based on body surface area, once a day for 3 months.

ACEI/ARB: The control group was only given oral ACEI/ARB for 3 months.

Study summary

Henoch-Schönlein purpura nephritis (HSPN) is the most common secondary glomerular disease in children. About 40% of HSPN cases are accompanied by mild proteinuria, and some of them progress to end-stage renal disease. Currently, the treatment for children with mild proteinuria HSPN mainly involves ACEI/ARB, but long-term use of these drugs can lead to an increase in aldosterone levels, affecting therapeutic efficacy. Finerenone can improve vascular endothelial cell dysfunction and renal tissue inflammation and fibrosis, and reduce urinary protein in patients with glomerular diseases. This study intends to conduct an exploratory randomized controlled clinical trial of finerenone in children with HSPN accompanied by a small amount of proteinuria to evaluate the efficacy and safety of finerenone treatment.

Eligibility

Primary outcome measure(s)

• Percentage of Subjects with a Reduction in 24-Hour Urinary Protein Excretion ≥30% from Baseline — 3 months

Trial sites (1)

Other trials for the same condition